Postes actifs de R. Mark Payne
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Chondrial Therapeutics, Inc.
 Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Directeur/Membre du Conseil | - | - |
| Directeur Technique/Scientifique/R&D | - | - | |
| Fondateur | - | - |
Historique de carrière de R. Mark Payne
Statistiques
Internationale
| Etats-Unis | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectorielle
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Chondrial Therapeutics, Inc.
Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Health Technology |
- Bourse
- Insiders
- R. Mark Payne
- Expérience
